Cargando…
Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The result...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267677/ https://www.ncbi.nlm.nih.gov/pubmed/34202163 http://dx.doi.org/10.3390/ijms22136846 |
_version_ | 1783720194149974016 |
---|---|
author | Swe, Hla Nu Sritularak, Boonchoo Rojnuckarin, Ponlapat Luechapudiporn, Rataya |
author_facet | Swe, Hla Nu Sritularak, Boonchoo Rojnuckarin, Ponlapat Luechapudiporn, Rataya |
author_sort | Swe, Hla Nu |
collection | PubMed |
description | Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The results indicated that lusianthridin inhibited arachidonic acid, collagen, and adenosine diphosphate (ADP)-stimulated platelet aggregation (IC(50) of 0.02 ± 0.001 mM, 0.14 ± 0.018 mM, and 0.22 ± 0.046 mM, respectively). Lusianthridin also increased the delaying time of arachidonic acid-stimulated and the lag time of collagen-stimulated and showed a more selective effect on the secondary wave of ADP-stimulated aggregations. Molecular docking studies revealed that lusianthridin bound to the entrance site of the cyclooxygenase-1 (COX-1) enzyme and probably the active region of the cyclooxygenase-2 (COX-2) enzyme. In addition, lusianthridin showed inhibitory effects on both COX-1 and COX-2 enzymatic activities (IC(50) value of 10.81 ± 1.12 µM and 0.17 ± 1.62 µM, respectively). Furthermore, lusianthridin significantly inhibited ADP-induced suppression of cAMP formation in platelets at 0.4 mM concentration (p < 0.05). These findings suggested that possible mechanisms of lusianthridin on the antiplatelet effects might act via arachidonic acid-thromboxane and adenylate cyclase pathways. |
format | Online Article Text |
id | pubmed-8267677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82676772021-07-10 Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation Swe, Hla Nu Sritularak, Boonchoo Rojnuckarin, Ponlapat Luechapudiporn, Rataya Int J Mol Sci Article Lusianthridin is a phenanthrene derivative isolated from Dendrobium venustum. Some phenanthrene compounds have antiplatelet aggregation activities via undefined pathways. This study aims to determine the inhibitory effects and potential mechanisms of lusianthridin on platelet aggregation. The results indicated that lusianthridin inhibited arachidonic acid, collagen, and adenosine diphosphate (ADP)-stimulated platelet aggregation (IC(50) of 0.02 ± 0.001 mM, 0.14 ± 0.018 mM, and 0.22 ± 0.046 mM, respectively). Lusianthridin also increased the delaying time of arachidonic acid-stimulated and the lag time of collagen-stimulated and showed a more selective effect on the secondary wave of ADP-stimulated aggregations. Molecular docking studies revealed that lusianthridin bound to the entrance site of the cyclooxygenase-1 (COX-1) enzyme and probably the active region of the cyclooxygenase-2 (COX-2) enzyme. In addition, lusianthridin showed inhibitory effects on both COX-1 and COX-2 enzymatic activities (IC(50) value of 10.81 ± 1.12 µM and 0.17 ± 1.62 µM, respectively). Furthermore, lusianthridin significantly inhibited ADP-induced suppression of cAMP formation in platelets at 0.4 mM concentration (p < 0.05). These findings suggested that possible mechanisms of lusianthridin on the antiplatelet effects might act via arachidonic acid-thromboxane and adenylate cyclase pathways. MDPI 2021-06-25 /pmc/articles/PMC8267677/ /pubmed/34202163 http://dx.doi.org/10.3390/ijms22136846 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Swe, Hla Nu Sritularak, Boonchoo Rojnuckarin, Ponlapat Luechapudiporn, Rataya Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title | Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title_full | Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title_fullStr | Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title_full_unstemmed | Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title_short | Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation |
title_sort | inhibitory mechanisms of lusianthridin on human platelet aggregation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267677/ https://www.ncbi.nlm.nih.gov/pubmed/34202163 http://dx.doi.org/10.3390/ijms22136846 |
work_keys_str_mv | AT swehlanu inhibitorymechanismsoflusianthridinonhumanplateletaggregation AT sritularakboonchoo inhibitorymechanismsoflusianthridinonhumanplateletaggregation AT rojnuckarinponlapat inhibitorymechanismsoflusianthridinonhumanplateletaggregation AT luechapudipornrataya inhibitorymechanismsoflusianthridinonhumanplateletaggregation |